業績紹介

Achivement

2017年業績

• Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B and Kumada H.

  Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.

  Hepatology. 2017; In Press.

• Nakano R, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, Shimizu S, Arihiro K, Imamura M, Chayama K, Tanaka Y and Ohdan H.

  Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report.

  Transplant Proc. 2017; 49: 1634-1638.

• Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C and Chayama K.

  Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

  Antimicrob Agents Chemother. 2017; 61: 9.

• Honda Y, Aikata H, Honda F, Nakano N, Nakamura Y, Hatooka M, Morio K, Kobayashi T, Fukuhara T, Nagaoki Y, Kawaoka T, Hiramatsu A, Imamura M, Kawakami Y and Chayama K.

  Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid.

  Hepatol Res. 2017; 47: 1053-1060.

• Kiso M, Yoshihara M, Ito M, Inoue K, Kato K, Nakajima S, Mabe K, Kobayashi M, Uemura N, Yada T, Oka M, Kawai T, Boda T, Kotachi T, Masuda K, Tanaka S and Chayama K.

  Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.

  Gastric Cancer. 2017; 20: 764-771.

• Sumimoto K, Tanaka S, Shigita K, Hayashi N, Hirano D, Tamaru Y, Ninomiya Y, Oka S, Arihiro K, Shimamoto F, Yoshihara M and Chayama K.

  Diagnostic performance of Japan NBI Expert Team classification for differentiation among noninvasive, superficially invasive, and deeply invasive colorectal neoplasia.

  Gastrointest Endosc. 2017; 86: 700-709.

• Hamana A, Takahashi Y, Uchida T, Nishikawa M, Imamura M, Chayama K and Takakura Y.

  Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.

  Antiviral Res. 2017; 146: 130-138.

• Nagai K, Ueno Y, Tanaka S, Hayashi R, Shinagawa K and Chayama K.

  Polysaccharides derived from Ganoderma lucidum fungus mycelia ameliorate indomethacin-induced small intestinal injury via induction of GM-CSF from macrophages.

  Cell Immunol. 2017; 320: 20-28.

• Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E and Japan Study Group of Nonalcoholic Fatty Liver D.

  Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.

  Hepatol Commun. 2017; 1: 780-791.

• Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T and Miyoshi E.

  Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.

  Hepatol Commun. 2017; 1: 780-791.

• Tamaru Y, Oka S, Tanaka S, Nagata S, Hiraga Y, Kuwai T, Furudoi A, Tamura T, Kunihiro M, Okanobu H, Nakadoi K, Kanao H, Higashiyama M, Arihiro K, Kuraoka K, Shimamoto F and Chayama K.

  Long-term outcomes after treatment for T1 colorectal carcinoma: a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group.

  J Gastroenterol. 2017; 52: 1169-1179.

• Ninomiya Y, Oka S, Tanaka S, Boda K, Yamashita K, Sumimoto K, Hirano D, Tamaru Y, Shigita K, Hayashi N, Matsuo T and Chayama K.

  Clinical impact of surveillance colonoscopy using magnification without diminutive polyp removal.

  Dig Endosc. 2017; 29: 773-781.

• Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Aikata H, Hayes CN, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K and Chayama K.

  Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.

  J Med Virol. 2017; 89: 1963-1972.

• Uchida T, Imamura M, Kan H, Hiraga N, Hayes CN, Tsuge M, Abe-Chayama H, Aikata H, Makokha GN, Miki D, Ochi H, Ishida Y, Tateno C and Chayama K.

  Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.

  J Gen Virol. 2017; 98: 1040-1047.

• Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V and Wiegand J.

  Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

  J Hepatol. 2017; 66: 1022-1030.

• Ono C, Fukuhara T, Motooka D, Nakamura S, Okuzaki D, Yamamoto S, Tamura T, Mori H, Sato A, Uemura K, Fauzyah Y, Kurihara T, Suda T, Nishio A, Hmwe SS, Okamoto T, Tatsumi T, Takehara T, Chayama K, Wakita T, Koike K and Matsuura Y.

  Characterization of miR-122-independent propagation of HCV.

  PLoS Pathog. 2017; 13: e1006374.

• Fukuhara T, Yamamoto S, Ono C, Nakamura S, Motooka D, Mori H, Kurihara T, Sato A, Tamura T, Motomura T, Okamoto T, Imamura M, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y, Chayama K and Matsuura Y.

  Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity.

  Sci Rep. 2017; 7: 45228.

• Kawaoka T, Aikata H, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Kobayashi T, Nagaoki Y, Nakahara T, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y and Chayama K.

  Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.

  Oncology. 2017; 92: 335-346.

• Hayes CN and Chayama K.

  Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses.

  J Med Virol. 2017; 89: 388-396.

• Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES and Kumada H.

  Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

  J Gastroenterol. 2017; 52: 385-395.

• Shigita K, Oka S, Tanaka S, Sumimoto K, Hirano D, Tamaru Y, Ninomiya Y, Asayama N, Hayashi N, Shimamoto F, Arihiro K and Chayama K.

  Long-term outcomes after endoscopic submucosal dissection for superficial colorectal tumors.

  Gastrointest Endosc. 2017; 85: 546-553.

• Urabe A, Imamura M, Tsuge M, Kan H, Fujino H, Fukuhara T, Masaki K, Kobayashi T, Ono A, Nakahara T, Kawaoka T, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Maki N, Ohdan H and Chayama K.

  The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.

  J Gastroenterol. 2017; 52: 366-375.

• Morio K, Imamura M, Kawakami Y, Morio R, Kobayashi T, Yokoyama S, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Makokha GN, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K and Chayama K.

  Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.

  J Gastroenterol Hepatol. 2017; 32: 645-650.

• Mori N, Imamura M, Kawakami Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Takaki S, Tsuji K, Chayama K and Hiroshima Liver Study G.

  IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.

  Hepatol Res. 2017; 47: E5-E13.

• Hayes CN and Chayama K.

  Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.

  Expert Rev Clin Pharmacol. 2017; 10: 583-594.

• Sato K, Chayama K, Alves K, Toyoda H, Suzuki F, Kato K, Rodrigues L, Jr., Zhang X, Setze C, Pilot-Matias T, Burroughs M, Redman R and Kumada H.

  Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.

  Adv Ther. 2017; 34: 1449-1465.

• Morio K, Imamura M, Kawakami Y, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Makokha GN, Ochi H, Amano H, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K and Hiroshima Liver Study G.

  ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.

  J Gastroenterol. 2017; 52: 746-753.

• Kobayashi T, Aikata H, Kobayashi T, Ohdan H, Arihiro K and Chayama K.

  Patients with early recurrence of hepatocellular carcinoma have poor prognosis.

  Hepatobiliary Pancreat Dis Int. 2017; 16: 279-288.

• Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T and Chayama K.

  Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.

  Antimicrob Agents Chemother. 2017; 61.

• Nakamura Y, Aikata H, Fukuhara T, Honda F, Morio K, Morio R, Hatooka M, Kobayashi T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Kobayashi T, Ohdan H, Shiroma N, Arihiro K and Chayama K.

  Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection.

  Hepatol Res. 2017; 47: 767-772.

• Chayama K and Hayes CN.

  Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.

  J Gastroenterol. 2017; 52: 125-126.

• Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, Nakamura H, Tanaka A, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Abe M, Nakao K, Yamagiwa S, Kaneko S, Honda M, Umemura T, Ichida T, Seike M, Sakisaka S, Harada M, Yokosuka O, Ueno Y, Senju M, Kanda T, Shibata H, Himoto T, Murata K, Miyake Y, Ebinuma H, Taniai M, Joshita S, Nikami T, Ota H, Kouno H, Kouno H, Nakamuta M, Fukushima N, Kohjima M, Komatsu T, Komeda T, Ohara Y, Muro T, Yamashita T, Yoshizawa K, Nakamura Y, Shimada M, Hirashima N, Sugi K, Ario K, Takesaki E, Naganuma A, Mano H, Yamashita H, Matsushita K, Yamauchi K, Makita F, Nishimura H, Furuta K, Takahashi N, Kikuchi M, Masaki N, Tanaka T, Tamura S, Mori A, Yagi S, Shirabe K, Komori A, Migita K, Ito M, Nagaoka S, Abiru S, Yatsuhashi H, Yasunami M, Shimoda S, Harada K, Egawa H, Maehara Y, Uemoto S, Kokudo N, Takikawa H, Ishibashi H, Chayama K, Mizokami M, Nagasaki M, Tokunaga K and Nakamura M.

  Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population.

  Hum Mol Genet. 2017; 26: 650-659.

• Yoshimatsu R, Yamagami T, Ishikawa M, Kajiwara K, Fukumoto W, Aikata H, Chayama K, Baba Y and Awai K.

  Retrograde venography during balloon-occluded retrograde transvenous obliteration of gastric varices.

  Minim Invasive Ther Allied Technol. 2017; 26: 1-6.

• Hayes CN, Imamura M and Chayama K.

  The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.

  Expert Rev Gastroenterol Hepatol. 2017; 11: 103-113.

• Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, Kojima F, Arihiro K, Kawakami Y, Wardell CP, Shiraishi Y, Tanaka H, Nakano K, Maejima K, Sasaki-Oku A, Tokunaga N, Boroevich KA, Abe T, Aikata H, Ohdan H, Gotoh K, Kubo M, Tsunoda T, Miyano S, Chayama K, Yamaue H and Nakagawa H.

  Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors.

  J Hepatol. 2017; 66: 363-373.

• Morio R, Hyogo H, Hatooka M, Morio K, Kan H, Kobayashi T, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Masayasu Y and Chayama K.

  The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.

  J Gastroenterol. 2017; 52: 253-262.

• Hirano D, Oka S, Tanaka S, Sumimoto K, Ninomiya Y, Tamaru Y, Shigita K, Hayashi N, Urabe Y, Kitadai Y, Shimamoto F, Arihiro K and Chayama K.

  Clinicopathologic and endoscopic features of early-stage colorectal serrated adenocarcinoma.

  BMC Gastroenterol. 2017; 17: 158.

• Yoshifuku Y, Sanomura Y, Oka S, Kurihara M, Mizumoto T, Miwata T, Urabe Y, Hiyama T, Tanaka S and Chayama K.

  Evaluation of the visibility of early gastric cancer using linked color imaging and blue laser imaging.

  BMC Gastroenterol. 2017; 17: 150.

• Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Nelson Hayes C, Tsugawa K, Yokozaki M and Chayama K.

  Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury.

  J Gastroenterol. 2017; 52: 1252-1257.

• Cheng X, Xia Y, Serti E, Block PD, Chung M, Chayama K, Rehermann B and Liang TJ.

  Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.

  Hepatology. 2017; 66: 1779-1793.

• Ochi T, Kawaguchi T, Nakahara T, Ono M, Noguchi S, Koshiyama Y, Munekage K, Murakami E, Hiramatsu A, Ogasawara M, Hirose A, Mizuta H, Masuda K, Okamoto N, Suganuma N, Chayama K, Yamaguchi M, Torimura T and Saibara T.

  Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS.

  Sci Rep. 2017; 7: 10146.

• Sato K, Ohira M, Shimizu S, Kuroda S, Ide K, Ishiyama K, Kobayashi T, Tahara H, Shiroma N, Arihiro K, Imamura M, Chayama K and Ohdan H.

  Aggressive angiomyxoma of the liver: a case report and literature review.

  Surg Case Rep. 2017; 3: 92.

• Kiso M, Ito M, Boda T, Kotachi T, Masuda K, Hata K, Sasaki A, Kawamura T, Yoshihara M, Tanaka S and Chayama K.

  Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor - a multicenter study.

  Scand J Gastroenterol. 2017; 52: 828-832.

• Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, Aikata H, Nagata Y, Chayama K and Ohdan H.

  Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study.

  Int J Surg. 2017; 44: 223-228.

• Daijo K, Kawaoka T, Nakahara T, Nagaoki Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Hara K, Tajima G, Kobayashi M and Chayama K.

  Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia.

  Clin J Gastroenterol. 2017; 10: 383-387.

• Sagami S, Ueno Y, Tanaka S, Fujita A, Hayashi R, Oka S, Hyogo H and Chayama K.

  Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study.

  Hepatol Res. 2017; 47: 872-881.

• Nakamura Y, Imamura M, Kawakami Y, Teraoka Y, Daijo K, Honda F, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H and Chayama K.

  Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.

  J Med Virol. 2017; 89: 665-671.

• Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ohdan H and Chayama K.

  Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.

  Clin J Gastroenterol. 2017; 10: 179-184.

• Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, Okanoue T, Itoh Y, Mochida S, Toyoda H, Yoshiji H, Takaki S, Yatsuzuka N, Yodoya E, Iwasa T, Fujimoto G, Robertson MN, Black S, Caro L and Wahl J.

  The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.

  J Gastroenterol. 2017; 52: 520-533.

• Morio R, Imamura M, Kawakami Y, Morio K, Kobayashi T, Yokoyama S, Kimura Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Nelson Hayes C, Aikata H, Takahashi S, Miki D, Ochi H, Mori N, Takaki S, Tsuji K and Chayama K.

  Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.

  J Gastroenterol. 2017; 52: 504-511.

• Sumimoto K, Tanaka S, Shigita K, Hirano D, Tamaru Y, Ninomiya Y, Asayama N, Hayashi N, Oka S, Arihiro K, Yoshihara M and Chayama K.

  Clinical impact and characteristics of the narrow-band imaging magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team.

  Gastrointest Endosc. 2017; 85: 816-821.

• Mizumoto T, Sanomura Y, Tanaka S, Kuroki K, Kurihara M, Yoshifuku Y, Oka S, Arihiro K, Shimamoto F and Chayama K.

  Clinical usefulness of magnifying endoscopy for non-ampullary duodenal tumors.

  Endosc Int Open. 2017; 5: E297-E302.

• Sagami S, Ueno Y, Tanaka S, Fujita A, Niitsu H, Hayashi R, Hyogo H, Hinoi T, Kitadai Y and Chayama K.

  Choline Deficiency Causes Colonic Type II Natural Killer T (NKT) Cell Loss and Alleviates Murine Colitis under Type I NKT Cell Deficiency.

  PLoS One. 2017; 12: e0169681.

• Igawa A, Oka S, Tanaka S, Otani I, Kunihara S and Chayama K.

  Evaluation for the Clinical Efficacy of Colon Capsule Endoscopy in the Detection of Laterally Spreading Tumors.

  Digestion. 2017; 95: 43-48.

• Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Serikawa M, Aikata H, Ochi H, Ishida Y, Tateno C, Ohdan H and Chayama K.

  Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.

  PLoS One. 2017; 12: e0172412.

• Tsuboi T, Serikawa M, Sasaki T, Ishii Y, Fujimoto Y, Yamaguchi A, Ishigaki T, Shimizu A, Kurihara K, Tatsukawa Y, Miyaki E and Chayama K.

  Use of 4-Fr versus 6-Fr Nasobiliary Catheter for Biliary Drainage: A Prospective, Multicenter, Randomized, Controlled Study.

  Diagn Ther Endosc. 2017; 2017: 7156719.

• Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H and Chayama K.

  The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

  PLoS One. 2017; 12: e0182710.

• Nakano M, Oka S, Tanaka S, Igawa A, Kunihara S, Ueno Y, Ito M and Chayama K.

  Indications for Small-bowel Capsule Endoscopy in Patients with Chronic Abdominal Pain.

  Intern Med. 2017; 56: 1453-1457.

• Yoshifuku Y, Sanomura Y, Oka S, Kuroki K, Kurihara M, Mizumoto T, Urabe Y, Hiyama T, Tanaka S and Chayama K.

  Clinical Usefulness of the VS Classification System Using Magnifying Endoscopy with Blue Laser Imaging for Early Gastric Cancer.

  Gastroenterol Res Pract. 2017; 2017: 3649705.

• Kotachi T, Ito M, Yoshihara M, Boda T, Kiso M, Masuda K, Matsuo T, Tanaka S and Chayama K.

  Serological Evaluation of Gastric Cancer Risk Based on Pepsinogen and Helicobacter pylori Antibody: Relationship to Endoscopic Findings.

  Digestion. 2017; 95: 314-318.

• Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H and Chayama K.

  HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

  PLoS One. 2017; 12: e0187409.

• Ono A, Hayes CN, Akamatsu S, Imamura M, Aikata H and Chayama K.

  Retrospective Identification of Herpes Simplex 2 Virus-Associated Acute Liver Failure in an Immunocompetent Patient Detected Using Whole Transcriptome Shotgun Sequencing.

  Case Reports Hepatol. 2017; 2017: 4630621.